Interplay of Factors Leading to Adverse Drug Reactions in the Liver, A Personal Viewpoint 1 by Schaffner, Fenton
TilE YALE JOURNAL OF BIOLOGY AND MEDICINE 50 (1977), 489-495
Interplay of Factors Leading to Adverse Drug Reactions
in the Liver, A Personal Viewpoint1
FENTON SCHAFFNER
Mount Sinai School of Medicine of The City University of New York
Received January 26, 1977
Adverse drug reactions in liver involve formation ofa reactive metabolic intermediary ofthe drug, binding
of the intermediary to macromolecules in the cell, notably proteins in the plasma membrane, immunological
response to these altered proteins and attack against hepatocytes bearing these altered proteins by immune
mechanisms. At each step in this complex process many factors act to enhance or depress drug metabolism,
metabolite disposition, macromolecular binding, neoantigen formation, and the cell mediated and humoral
immune attack. The extent and direction of each step may be dose dependent but the complexity of the
overall mechanism is so immense that predictability of hepatic drug reactions is unlikely in most instances.
Adverse drug reactions involving the liver were considered originally to be "idio-
syncratic" in nature without further defining this term. When allergy became under-
stood as an immunologic phenomenon, the reactions were felt to be the result of
hypersensitivity with drugs acting as haptens. As more were seen, the reactions were
classified into direct toxicity, cholestasis and viral hepatitis-like [1]. The first was
described as the result of dose related injurious action of the drug leading to cell
death, the second as the result of impairment of function of the bile secretory
apparatus of the hepatocyte, rather than interference with bile flow by ductular
obstruction, and the third, as the result of a hypersensitivity reaction. The details of
metabolism for many drugs have been elucidated now and intermediary metabolites
formed in the hepatocyte have been blamed for injury rather than the drug itself[2].
The purpose of this paper is to examine aspects of both metabolism and immune
responsiveness and to hypothesize how a complex interplay of several factors is
probably necessary to produce many of the adverse reactions in the liver.
THE METABOLIC FATE OF DRUGS
A drug given by mouth is carried to the liver via the portal vein bound to serum
proteins, most often albumin. The transfer across the hepatocellular plasma mem-
brane probably requires polysaccharide binding sites on the external surface attached
to integral membrane proteins ofthe hepatocytes. Whether the drug is taken into the
cell by endocytosis, by a change in the shape or position of the membrane protein or
by dissolution in the lipid bilayer ofthe membrane is unknown. Once inside the cell
the drug is eventually bound to a heme containing cytoplasmic cytochrome in the
smooth endoplasmic reticulum. At least two [3] and perhaps many [4] cytochromes
are present. The one metabolizing mainly aliphatic compounds is called cytochrome
P-450 because its maximal absorbance of light in carbon monoxide atmospheres
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occurs at 450 nanometers. The one which metabolizes mainly aromatic compounds is
called P1 450 or P-448 and is associated with aryl hydrocarbon hydroxylase. These
cytochromes in the drug metabolizing enzyme system can be induced by the drug
causing a reaction or by other drugs or chemicals [5,6]. The drug can be oxidized or
deacylated by the cytochrome to the form ofthe drug that is active pharmacologically
[7]. Then it is further oxidized and conjugated with glucuronide or ifa large amount
is present with glutathione. Occasionally the drug moves to the soluble fraction ofthe
cytoplasm where sulfatation or acetylation can occur.
Oxidation to Reactive Intermediaries
The initial metabolic step involves oxidation at one carbon atom or one double
bond with formation of an oxidized intermediary and water. The cytochrome P450
requires molecular oxygen and the enzyme system has been called a "mixed function
oxidase." The intermediary which forms in the initial stages of oxidation is an
epoxide, a superoxide or a free radical [8,9]. It usually has a short halflife but it can
escape further metabolism. The metabolite is very reactive and can bind to cell
macromolecules like protein, RNA and DNA. Some of the macromolecules are
structural components, some are enzymes and some are informational in nature. The
intermediary metabolites ofa given drug probably bind preferentially to specific sites
on a given macromolecule because toxic reactions are reproducible often even in
different species. The effect of such binding depends on the rate offormation ofthe
intermediary as well as on the type of macromolecule bound. The intermediary free
radical formed from carbon tetrachloride, for instance, destroys the lipoprotein
membrane of the endoplasmic reticulum. The acute centrolobular hepatic necrosis
following tumor chemotherapy with such drugs as mithramycin [10] ormitomycin C
[11] or from overdosage of acetaminophen [12] probably results from metabolite
binding to macromolecules, the last as suggested by Mitchell et al [7,9]. The rate of
formation of metabolites in turn is in part genetically controlled [13,14] but also
individual factors play a role. The amount ofenzyme depends directly on the state of
protein nutrition [15] and on how much it is induced by environmental pollutants
[16] or by preceding drug therapy [6]. Its state of reactivity can be influenced by
competition for metabolism by endogenous substances or by other drugs or by
hepatocellular injury from disease.
Disposition ofIntermediaries
Normally intermediaries are moved by continuation ofthe oxidative process with
the help of enzymes such as epoxide hydrase [17] until a more stable and polar
intermediate is formed. This intermediate is then conjugated with a polarcompound
making the original drug, which was usually non-polar, polar and readily excreted
into the urine or bile depending upon its molecular weight. When more intermediary
is formed than the normal pathway can handle a back up mechanism may be
available in that the excess is scavenged by secondary and nonspecific pathways.
These involve combining with glutathione or with vitamin E and probably other
pathways. The former combinations can be further metabolized to form mercaptides
which are secreted in bile or urine. Little is known of the role of these pathways in
drug metabolism, let alone in adverse drug reactions and therefore much ofwhat can
be said is speculative. Indeed the subject ofglutathione in the liver was the subject of
a workshop held recently (Arias IM, Jakoby WB: Glutathione: Acetabolism and
Function. New York: Raven Press, 1975, p 377). The rate ofdegradation ofescaped
intermediaries depends on the activity of the epoxide hydrase, on the availability of
substrate for conjugation and on the amount of glutathione or pantothenic acid
490HEPATIC DRUG REACTIONS
available for scavenging. Induction of metabolic enzyme activity by preceding drug
administration or by environmental factors may accelerate formation of intermedi-
aries on one hand and their removal through conjugation on the other. Competition
for conjugation can also cause release of more reactive intermediaries. The effects of
acetamenophen overdosage may exhaust the primary conjugation pathway and the
supply ofglutathione, thereby permitting the excess reactive intermediary to bind to
vital cell macromolecules. This consideration has led to the prophylactic and thera-
peutic use of sulfur containing amino acids or analogues [18].
ALTERATIONS IN HEPATOCYTIC PLASMA MEMBRANES
The plasma membrane is a lipid bilayer with external and internal surfaces
consisting ofthe hydrophilic ionic portion ofthe fatty acids and phospholipids, and a
liquid hydrophobic central portion [19,20] (see these references for specific drug
effects mentioned in what follows). Protein molecules are scattered throughout the
bilayer. These proteins called integral membrane proteins are necessary to maintain
the membrane. They have hydrophilic portions which protrude above the membrane
surface or below it into the cytoplasm or in both directions and hydrophobic portions
held in the lipid center ofthe membrane bilayer. Carbohydrate moieties attached to
the hydrophilic portion of the integral membrane protein protruding above the cell
surface are specific receptors which bind hormones, antibodies and other substances
that enter the cell or otherwise influence the interior of the cell. The distribution of
the protein molecules in the membrane varies depending on the substances that bind
to their receptor sites, the physical contacts of the cell and on cytoplasmic skeletal
elements. The last are rigid microtubules anchoring membrane proteins or contractile
microfilaments moving them about in the membrane. Drugs can influence the
cytoskeletal structure associated with the plasma membrane and its control in many
ways. Some substances cause aggregation of integral membrane proteins to form
small clusters or larger caps which then enter the cell by endocytosis. [20]. This
clustering can be prevented by drugs which injure cellular function in a nonspecific
fashion, but it also can be prevented by drugs like colchicine or vinblastine which
depolymerize the protein tubulin of the microtubules or like cytochalasin B which
disrupts microfilaments. Some drugs enhance aggregation of membrane protein like
the tertiary amine anesthetics [20]. Probably many drugs or their metabolites influ-
ence the cytoskeletal structure by directly affecting microtubules and microfilaments
or by nonspecifically interfering with cellular function. Furthermore interactions of
drugs may alter the cell membrane in complex ways so that membrane proteins are
internalized or shed. The process of shedding exposes hitherto "unseen" portions of
the membrane proteins to the immune system of the body thereby stimulating an
immune response. Finally reactive intermediary metabolites of drugs may bind to
specific proteins in the plasma membranes like those that are part ofthe HLAantigen
complex. The patient's immune surveillance mechanism may therefore not recognize
this altered protein as self and attack the entire cell injuring it or rejecting it. Thus
drugs taken up and metabolized by hepatocytes not only alter the internal composi-
tion of these cells but also their surfaces. As yet unknown factors govern the rates of
synthesis, polymerization and orientation of the cytoskeletal proteins tubulin of
microtubules and actin and myosin of microfilaments.
IMMUNOLOGICAL RESPONSE TO PLASMA MEMBRANE ALTERATIONS
The presence of abnormal membrane proteins or the exposure of shed integral
membrane proteins or the more easily detached nonessential peripheral membrane
proteins may induce humoral antibody formation as well as a cell mediated immune
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response. Such mechanisms have been proposed for hepatitis B [21, 22] and they may
also be suggested to be acting in the drug induced viral hepatitis-like reactions
occurring after halothane [23], methyldopa [24] or isoniazid [25]. Indeed a similar
pathogenesis may explain the similar clinical and pathological picture of viral and
drug induced hepatitis. In the case of methyldopa, a superoxide anion has been said
to be responsible [26]. The nature and intensity ofthis response depends on the rate
of release of the surface proteins, their uptake by macrophages or leukocytes or
binding to the surfaces of lymphocytes, their antigenicity and the reactivity of the
host immune system. Plasma membrane fragments, such as those that may be
released by shedding of cytoplasm from an injured cell, are ingested by Kupffer cells
and leukocytes setting up foci of inflammation [27]. Drugs or their metabolites may
influence many steps in this complex process by determiningthe rate at which protein
is made available to act as an antigen, the phagocytic ability of macrophages and
their lysosomal digestive function, the surface binding of lymphocytes, the rate of
antibody formation and the rate ofproduction ofspecifically cloned lymphocytes and
finally the availability of receptor sites on the hepatocellular surface for immune
reactions. Drugs even compete with their metabolites in some of these processes.
Hepatocellular injury may play an adjuvant role enhancing immune responsiveness
on one hand and a suppressing role on the other by slowing drug metabolism or
reducing available receptor sites. The hepatocellular injury also stimulates collagen
production and deposition. The fibrosis may play a role in the development of
chronic hepatitis first described after long term use ofthe laxative, oxyphenisatin [28]
and now even recognized after prolonged aspirin ingestion [29]. The pericellular
fibrosis along with the development of a complete basement membrane may consti-
tute a physical barrier which can interfere with blood-liverexchange ofnutrients and
oxygen [30]. This barrier may also be protective by keeping antibody molecules and
killer lymphocytes away from the hepatocellular surface.
OPPOSING FORCES IN ADVERSE REACTIONS
Opposing forces are active at each step ofdrug uptake, metabolism and disposition
of metabolites as well as at each step offormation ofneoantigens and response ofthe
body to these proteins (Table 1). Genetic factors play a major role in all ofthese steps
but, except for slow and fast acetylaters of some drugs like isoniazid and for
congenital defects in immune responsiveness, little is known about genetic control
[14,31]. The rate of the initial step in metabolism can be accelerated by induction of
the responsible enzymes by environmental pollutants like pesticides [32] or poly-
chlorinated biphenyls [33], other drugs or even the drug in question. Liver cellinjury
can reduce the rate of drug metabolism as can any viral infections which induce
interferon. Indeed all natural or synthetic interferon inducers drastically reduce the
rate ofdrug metabolism by decreasingthe activity ofcytochrome P450[34]. The rate
can be decreased byprotein malnutrition and by competition fromendogenous or the
same exogenous factors just mentioned. Similarly the rate of disposition of the
reactive intermediary metabolite via the normal detoxification pathways can be
accelerated by induction and slowed by competition. The rate of repair of macro-
molecules altered by drug metabolite binding varies under different physiological and
pharmacological circumstances. The binding sites on the cell macromolecules may
also be competitively blocked by other substances or they may be altered bychanges
in macromolecular conformation because the cytoskeleton is altered by drugs of
cellular injury. Organs other than the liver may also participate in the metabolism
and disposition of some drugs and the rates, pathways and organs involved in drug
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metabolism vary from species to species so that extrapolation ofexperimental studies
to man is possible only if metabolism is similar [35].
PREDICTABILITY OF DRUG REACTIONS
Thus to produce cellular injury a drug and its metabolites must wind their way
through a devious pathway filled with detours and obstacles as well as rapid slides.
Only with the direct toxins are the pathways simple enough to quantitate so that dose
relations can be established. With most drugs that cause adverse reactions, predicta-
bility itself is not yet possible. Dose relationships probably exist in individual cases
and at each step, but these are lost in the complexity of metabolic reactions some of
which amplify and others diminish the effect ofthe drug in question. The multiplicity
of effects at each step also makes prevention a distant goal.
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